Propanc Biopharma disclosed its half‑year financial results for the six months ended December 31, 2025, showing a cash balance of $561,237 and an accumulated deficit of $134.48 million. The figures reflect the company’s ongoing cash burn and the need for additional financing to support its clinical program.
The company’s balance sheet also shows a $100 million private‑placement facility that has been partially drawn. Initial proceeds of $1.5 million were received, including $1 million from the issuance of 100 shares of Series C Convertible Preferred Stock and an additional $500,000 when 50 shares were exercised. The facility provides a critical liquidity buffer as the company prepares for a Phase 1b first‑in‑human study of its lead candidate, PRP, in advanced cancer patients.
On the income‑statement side, Propanc recorded a net loss of $7.9 million for the six months ended December 31, 2025, compared with a net loss of $784,493 for the same period in 2024. The widening loss is driven by $8.3 million of operating expenses, largely composed of administrative costs and stock‑based compensation. The company has no revenue in the period, reflecting its development‑stage status.
In addition to the financial results, Propanc announced the filing of four provisional patent applications in Australia. The filings are part of a broader strategy to expand the company’s intellectual‑property portfolio from roughly 90 patents to over 200, covering proenzyme formulations and new therapeutic indications. CEO James Nathanielsz emphasized that the IP expansion will support the company’s clinical development and help secure its leadership position in the field.
Management reiterated its focus on accelerating the clinical development of PRP and on strengthening the balance sheet. The company’s cash position remains limited, and it has acknowledged substantial doubt about its ability to continue as a going concern. The $100 million private‑placement facility is therefore viewed as essential to sustain operations until the next funding round or a milestone event.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.